Pralsetinib

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 261 publications

RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases.

RET Receptor Tyrosine Kinase Promotes Breast Cancer Metastasis to the Brain and RET Inhibitors Pralsetinib and Selpercatinib Suppress Breast Cancer Brain Metastases.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 17, 2025

Corneal edema and epithelial defect during pralsetinib treatment.

Corneal edema and epithelial defect during pralsetinib treatment.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 29, 2025

Pralsetinib-Induced Lymphocytic Colitis.

Pralsetinib-Induced Lymphocytic Colitis.

Journal: ACG case reports journal

Published: September 17, 2025

Pathological complete response in RET-positive non-small cell lung cancer: a case report of pralsetinib-based "sandwich" therapy.

Pathological complete response in RET-positive non-small cell lung cancer: a case report of pralsetinib-based "sandwich" therapy.

Journal: Translational lung cancer research

Published: August 22, 2025

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.

Journal: Frontiers in oncology

Published: August 11, 2025

The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production.

The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production.

Journal: Frontiers in pharmacology

Published: July 23, 2025

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.

Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.

Journal: Cancer letters

Published: June 03, 2025

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: June 03, 2025

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Journal: Biomarker research

Published: May 24, 2025

Design and Synthesis of 2-Aminopyrazolpyrimidopyridone Derivatives as RETV 804M and RETG 810C Kinase Inhibitors.

Design and Synthesis of 2-Aminopyrazolpyrimidopyridone Derivatives as RETV 804M and RETG 810C Kinase Inhibitors.

Journal: Chemical biology & drug design

Published: May 15, 2025

Showing 1-12 of 261

Last Updated: 02/24/2026